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impact, price, price against comparator, and innovation. The results in the two disease 
areas were separately analyzed and then compared with each other qualitatively on 
the basis depth of the responses. RESULTS: Awareness about the evidence expecta-
tions were seen to vary substantially between the disease areas. Payers were seen to 
be far more conscious in the high-burden disease area. Of the 12 stakeholders inter-
viewed for the high-burden disease area (cardiovascular disease used as an example), 
all of them could provide an in-depth understanding of the value drivers for a new 
drug. On the other hand, of the stakeholders interviewed from a low-burden disease 
area within urology, a very small part of the sample (n = 2) was able to provide details 
about necessary expectations for the indication. CONCLUSIONS: The variation in 
awareness among payers in disease areas tends to affect the clinical outcomes that are 
presented by the drug manufacturer for a novel drug for the indication. The low 
awareness regarding evidence expectations in disease areas with low budgetary impact 
may lead to lower quality of evidence being accepted for reimbursement. This needs 
to be further investigated. 
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OBJECTIVES: The number of economic-evaluations (EE) increases but their role in 
decision-making remains unclear. Our literature review of the use of EE in decision-
making at macro-level aimed to analyze the methods presented in the articles and to 
investigate differences within and between countries regarding the use of EE, its facili-
tators and barriers. METHODS: We searched major databases (PubMed, Web-of-
Science, Euronheed, EconLit) in seven languages, without time limit, using keywords 
related to economics, health care policy decision-making, and outcomes research. 
Abstracts were screened according to four criteria reﬂ ecting the objectives of our 
review. Selected articles were analyzed and compared using a checklist of items related 
to study context (period, location, domain . . .), methods (population, design . . .), 
and outcomes (use of EE, facilitators, barriers . . .). RESULTS: Twenty-nine articles 
were selected. Most reported single-country- (24), mainly developed-country-studies 
(20). Five multi-country-studies compared countries of Europe, the USA and Latin-
America. The studies’ population generally included public or private health authori-
ties and used questionnaires (10), interviews (6), focus-groups (1), observations (4) or 
a combination of interviews and other methods (8). The main facilitator to using EE 
in decision-making was governmental/institutional incentives (UK and Australia). 
Although the use of EE has increased since the late 1990s, barriers remain, without 
apparent variation, overtime and between countries. Most relate to the accessibility 
and acceptability of EE. CONCLUSIONS: Decision-makers are increasingly aware of 
the importance of using EE in their practice. Despite large differences in the level of 
EE use between countries, barriers are very similar. Studying these barriers could 
narrow gaps between researchers and decision-makers and encourage governmental 
incentives to using EE. Consequently, we decided to develop a methodology for assess-
ing the use of EE in radiotherapy decision-making, a domain where many EE have 
been undertaken, without actually investigating their use. This study will be conducted 
in France, and in European or developing-countries.
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OBJECTIVES: In cost-utility analyses (CUA), utility values are rarely available for the 
entire patients sample and they are generally predicted using a “mapping” interpola-
tion from a functional status questionnaire, known for the entire sample. This 
mapping method is not accounted for in pharmaceutical industry and in literature 
studies, when building conﬁ dence regions around the utility and the incremental cost-
utility ratio, leading to a wrong conﬁ dence region and consequently, to a wrong 
decision-making. The purpose of this paper is to build a conﬁ dence interval (CI) 
around the mean utility, accounting for the uncertainty coming from the “mapping” 
interpolation. METHODS: Analytical and bootstrap methods are developed to handle 
the fact that values are interpolated. Linear, multilinear, and nonlinear mapping are 
considered. Monte Carlo experiments are carried out to compare the performance of 
these methods. These methodologies are applied on data issued from an observational 
study dealing with prostate cancer treatment. Utility is assessed with Standard Gamble 
method and some of these values are interpolated from the questionnaires: EORTC 
QLQC-30; IPSS and IIEF-5; SF-36 and Visual Analogic Scales. RESULTS: Monte 
Carlo experiments show that the analytic and bootstrap 95% CI display coverage 
between 94% and 96% for various sample sizes. If mapping is not accounted for 
(“naive method”), the coverage is between 20% and 40%. The cross validation shows 
similar results. From prostatectomy data, the utility is explained by SF-36, role func-
tioning, diarrhea, and age. For instance, mean utility equals 0.94. The analytic and 
bootstrap CIs equal [0.59, 1.51] and [0.51, 1.63] respectively. The naive interval 
equals [0.95, 1.15]. CONCLUSIONS: In CUA, decision-making based on utility 
values interpolated from mapping is not reliable: a naive interval would lead to a 
serious mistake. The uncertainty due to mapping has to be accounted for. Our analytic 
and bootstrap procedures, integrating the mapping, provide very accurate results.
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BACKGROUND: Two types of mapping exercises have been suggested to translate 
data from the short-form health instrument SF-12 into measurements for the EQ-5D 
instrument. One of the trends associates SF-12 data directly to the EQ-5D index, 
whereas a second approach suggests a response mapping method where SF-12 data 
have been mapped to the ﬁ ve domains of the EQ-5D questionnaire. OBJECTIVES: 
To improve the current response mapping approach and provide a comparison 
between the direct and the response mapping approaches to the EQ-5D. METHODS: 
Five multinomial logit regressions were implemented to estimate the association 
between SF-12 variables and each of the EQ-5D domains. Predicted EQ-5D responses 
were estimated using a Monte Carlo method. a parameter uncertainty approach was 
introduced to calculate conﬁ dence intervals for the predicted EQ-5D index. The direct 
mapping approach for the comparison was also conducted. Several large data sets 
were used for internal and external validation. Actual versus predicted EQ-5D index 
were compared using mean square error (MSE), mean absolute error (MAE), and 
conﬁ dence intervals. RESULTS: In the internal validation data set, both the response 
and direct mapping predicted a similar mean EQ-5D index, but the response mapping 
yielded a smaller MSE of 0.018 compared to 0.020 in the direct mapping, and a 
smaller MAE of 0.091 in the response mapping compared with 0.105 in the direct 
mapping method. Using the external validation data set, the MSE and MAE were one 
decimal point less in the response compared to the direct mapping. CONCLUSIONS: 
The revised response approach provided marginally better results than the direct 
mapping method. The response method can be implemented to country-speciﬁ c 
EQ-5D data with available value sets. To facilitate the implementation of the revised 
response mapping algorithm, a Stata command has been programmed.
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OBJECTIVES: Treatments of ocular hypertension (OHT) and glaucoma aim mainly 
at maintaining the patient’s visual function and related quality of life (QoL). However, 
it is not known to what extent the disease progression impacts the health-related QoL. 
Using recent publications, the objectives were to 1) derive a range of EQ-5D utility 
scores in OHT/glaucoma patients; (2) establish a direct, quantitative link between the 
mean defect in perimetry (MD) measured in decibels (db) and the utility loss; and (3) 
estimate the utility level of patients reaching a glaucoma stage. METHODS: The 
glaucoma stages were characterized using MD thresholds of 0 db (OHT), 0–6 db 
(early glaucoma), 6–12 db (moderate), 12–22 db (advanced), and >22 db (legal blind-
ness), as per the Hodapp classiﬁ cation. An algorithm allowing to derive EQ-5D utility 
scores from the eight mean subscale scores to the SF-36 (Ara and Brazier 2008) was 
applied to the range of SF-36 scores published in a systematic review of QoL in 
glaucoma (Mills 2009). Besides, the same algorithm was used to estimate the utility 
loss corresponding to a MD of 1 db, based on a regression model assessing the correla-
tion between visual function and QoL in glaucoma patients (Lin and Yang 2010). 
RESULTS: Over eight studies in OHT/glaucoma patients, utility scores ranged from 
0.65 to 0.89. Based on a signiﬁ cant regression coefﬁ cient for the SF-36 Role Physical 
subscale, a utility loss of 0.0295/db was calculated. Applying this utility loss/db to the 
predeﬁ ned thresholds, the ranges of unadjusted utility scores expected per glaucoma 
stage equal: 0.72–0.90 (early), 0.55–72 (moderate), 0.25–0.55 (advanced), and <0.25 
(blindness), assuming a baseline utility of 0.90 for OHT. CONCLUSIONS: These 
utility scores per disease stage are consistent with published direct measures of HUI3. 
The estimated utility loss per db is sizeable and could be implemented in cost-utility 
models where disease progression is tracked.
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OBJECTIVES: Anchor-based methods are frequently used for determining the 
minimal important difference (MID) of scales employed to measure patient-reported 
outcomes (PRO). The anchor may, e.g., consist of a global rating by the patient or 
the doctor or of a clinical measure closely related to the issue to be measured. The 
role of the psychometrical properties of the anchor has been rarely studied in this 
context. Aim of this contribution is to shed more light on the relationship between 
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the reliability of the anchor and the estimated MID. METHODS: We performed a 
simulation study in which the reliability of the anchor used for MID estimation was 
varied systematically. Features of real-life data (e.g., skewed distribution, discreteness 
of PRO scale) and anchors were used to generate simulated PRO scales and anchors. 
MIDs were then estimated on the basis of the simulated data. RESULTS: Compared 
to the MID value obtained with an anchor with perfect reliability (r = 1), a marked 
attenuation of the MID was observed when reducing the reliability of the anchor. 
Thus, an anchor with reliability 0.7 gave rise to a 24% to 35% decrease of the MID 
estimate and an anchor with reliability 0.5 led to a 45% to 55% reduction. Based on 
the ﬁ ndings and on theoretical considerations, we suggest a method for bias correction. 
CONCLUSIONS: When determining the MID of a PRO scale by an anchor-based 
method, the reliability of the anchor plays a crucial role. Anchors with poor to moder-
ate reliability may lead to considerable underestimation of the MID. Bias correction 
is possible provided the reliability of the anchor is known. 
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OBJECTIVES: Value-based pricing has recently been discussed by international orga-
nizations as a means to estimate a drug price that is linked to the beneﬁ ts it offers 
patients and society. However, one of the challenges with value-based pricing is 
determining the optimal threshold for health policy decision-making. The World 
Health Organization (WHO) has recommended using multiples of a country’s per 
capita GDP as the value threshold. In this study, pharmacoeconomic modeling was 
used to estimate a value-based monthly price for a hypothetical new cancer drug that 
provides a 3-month survival to patients with metastatic colorectal cancer (mCRC). 
METHODS: A decision model was developed to simulate progression free and overall 
survival in mCRC patients receiving standard chemotherapy ± the new drug. Out-
comes for cancer control and side effects were abstracted from randomized trials in 
mCRC. Costs for chemotherapy were obtained from Canadian cancer centers. Utility 
estimates measured as quality-adjusted life-years (QALYs) were determined by inter-
viewing 24 oncology nurses and pharmacists using the Time Trade-Off technique. The 
monthly price of the new drug was then modeled using a threshold of $117,000 per 
QALY gained, which is three times the Canadian per capita GDP, as recommended 
by the WHO. RESULTS: The analysis suggested that a monthly price of $2180 would 
be considered cost-effective from the Canadian public health perspective. If the drug 
were able to improve patient quality of life or survival from 3 to 6 months, the monthly 
price could increase to $4100 and $3430 and offer the same value. CONCLUSIONS: 
The use of the WHO criteria for estimating a value-based price is feasible. However, 
one of the challenges would be to identify an appropriate threshold that would provide 
a balance between what governments can afford to pay and the commercial viability 
of the product in the reference country.
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OBJECTIVES: Many countries are adapting their pharmaceutical reimbursement 
system, increasingly emphasizing the role of pharmacoeconomics in decision-making. 
The aim of our study is to analyze European regulatory systems to obtain insight into 
best practice systems that deliver value for money. METHODS: The analytical Hutton 
Framework was used for comparing and assessing “fourth hurdle” drug reimburse-
ment systems in the The Netherlands, Belgium, Sweden, and France. We investigated 
policy documents, explored literature, and conducted interviews with policymakers 
and representatives of the pharmaceutical industry. RESULTS: All systems have a 
centralized decision body, even though the ﬁ nancial responsibility may be regional 
(Sweden). Only in Sweden, the minister has no role at the individual reimbursement 
decision level. None of the systems has a fully independent evaluation process and the 
impact of the systems is mainly assessed on drug expenditure. All countries make 
efforts to increase transparency. However, in Sweden manufacturers may withdraw 
their application before the ﬁ nal reimbursement decision, guaranteeing conﬁ dentiality 
at the cost of less transparency. Policies to deal with uncertainty vary per country: 
ﬁ nancial risk-sharing agreements by price/volume contracts—France—versus out-
comes-based agreements for expensive inpatient drugs—the The Netherlands. The 
actual value of a drug and disease severity is reﬂ ected in the level of reimbursement 
in France and Belgium, whereas in the The Netherlands and Sweden, enlisted drugs 
are fully reimbursed. All countries attempt to increase the importance of pharmaco-
economics in decision-making. However, no country expresses the relative importance 
of cost-effectiveness compared to other criteria nor applies a strictly deﬁ ned threshold. 
CONCLUSIONS: This study reveals that while there is a convergence in scientiﬁ c 
evaluation processes, important differences remain between the Dutch, Belgian, 
Swedish, and French regulatory frameworks. All countries recognize that pharmaco-
economics has a place in decision-making on value for money, but for the time being, 
pharmacoeconomics seems to play a rather undeﬁ ned role.
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OBJECTIVES: Finnish retail prices for drugs are determined with a pricing scheme 
(PS). The PS is of the form “multiplier × wholesale price + ﬁ xed sum.” The multiplier 
ranges from 1.125 to 1.5 (being smaller for higher wholesale prices), whereas the ﬁ xed 
sum ranges from 0.5 to 47.68 euros (being larger for higher wholesale prices). 
Although PS is regressive, it nevertheless provides higher absolute pharmacy margins 
for drugs with higher wholesale prices. At the lower end of wholesale prices, PS results 
in retail prices that do not cover dispensing costs. Despite this, the retail prices (exclud-
ing VAT 8%) are used to represent all drug and drug delivery costs in economic evalu-
ations. This study assesses the impact of this Finnish system-derived “distortion” in 
cost-effectiveness analyses. METHODS: The cost utilities of new hypothetical treat-
ments were assessed in a setting where the new and old treatments produce different 
amounts of quality-adjusted life-years (QALYs) and the only cost difference comes 
from the pharmaceutical prices. The treatments are assumed not to differ regarding 
the real costs of drug delivery and patient survival. The PS-induced computational 
cost difference was deducted from the retail price differences of new and old treatments 
to estimate the impact of PS on the incremental cost-effectiveness ratios (ICER). 
RESULTS: The computational cost differences due to PS ranged from 7.3 to 1 951 
euros and the QALYs gained ranged from 0.004 to 0.070 in estimated scenarios. The 
respective ICERs increased by 104 to 487 840 euros/QALY due to the PS. CONCLU-
SIONS: The PS signiﬁ cantly worsens the ICERs obtained for more expensive and often 
innovative pharmaceuticals. The Finnish PS is problematic when the aim is to provide 
optimal, cost-effective treatments to Finnish patients. In the current form, the PS 
discourages innovation and may prevent reimbursement of otherwise cost-effective 
treatments.
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OBJECTIVES: To develop a framework for integrating pricing and reimbursement 
with health economics and outcomes research and health policy to achieve commer-
cially desirable prices and levels of access in 2010 and beyond. METHODS: A review 
of recent pricing policy and regulatory changes of countries, especially those in the 
ﬁ nancially troubled Eurozone, was conducted. This was supplemented by a review of 
P&R decisions for a selection of drug launches between 2005 and 2009 and catego-
rized according to the level of therapeutic innovation and disease type (conventional, 
rare diseases, oncology). a search was performed on the OHE and NHS EED databases 
and HTA reports to establish the level of published value evidence in support of these 
launches, and ﬁ nally, the components of most importance to a market access strategy 
were identiﬁ ed and validated through interviews across different stakeholder types. 
RESULTS: The review identiﬁ ed since January 2010, there have been 11 pricing policy 
and regulatory changes. From the review of recent P&R decisions and stakeholder 
interviews, the main components identiﬁ ed were: competitive and environmental 
analysis (market assessment, reimbursement, revenue forecasts, policy trends); analysis 
of payer’s decision drivers (payer, physician, and other stakeholder qualitative 
research); value demonstration (value hypotheses, economic modeling, patient-
reported outcomes, scientiﬁ c advice); pricing strategy (price targets, cross-market 
revenue optimization modeling, country launch sequencing, scenario planning); and 
local market access tactics (HTA, risk sharing, contracting negotiations with payers). 
The review of the P&R decisions also demonstrated an increasing trend toward 
deployment of risk-sharing schemes since 2008. CONCLUSIONS: Development of a 
successful market access strategy requires an understanding of pricing, health econom-
ics and outcomes research, health technology assessment (HTA), and health policy, 
and continually keeping vigilant and adapting to rapid changes in the policy environ-
ment. This research gives direction to health economics, P&R, and government affairs 
professionals for the development of an integrated framework for the design and 
implementation of a global market access strategy. 
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BACKGROUND: In literature, economic models of ﬂ u vaccination in elderly (65+) 
most often consider the target population as one homogeneous age group evaluated 
during a 1-year time period (= 1-year 65+ group cohort model). Because the mortality 
